Search research articles
Contact Us
Filters
Showing results (151-160 of 188) with videos related to
Page
of 19
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
December 5, 2023
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Thomas G Martin, Philippe Moreau, Saad Z Usmani, et al.
Leukemia
|
September 25, 2024
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
María-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
The Lancet. Haematology
|
October 7, 2018
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial
Niels Wcj van de Donk, Bronno van der Holt, Monique C Minnema, et al.
Hemasphere
|
November 15, 2019
Insights on Multiple Myeloma Treatment Strategies
María-Victoria Mateos, Heinz Ludwig, Ali Bazarbachi, et al.
Bone Marrow Transplantation
|
July 26, 2020
Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
Nico Gagelmann, Diderik-Jan Eikema, Liesbeth C de Wreede, et al.
The New England Journal of Medicine
|
February 24, 2021
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C Munshi, Larry D Anderson, Nina Shah, et al.
Haematologica
|
September 2, 2018
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Jo Caers, Laurent Garderet, K Martin Kortüm, et al.
The Lancet. Oncology
|
June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Heinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.
Blood
|
October 8, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
Luca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, et al.
Leukemia Research
|
March 26, 2014
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes
Michel Delforge, Dominik Selleslag, Yves Beguin, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 188) with videos related to
Sort By:
Page
of 19
Clinical Lymphoma, Myeloma & Leukemia
|
December 5, 2023
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Thomas G Martin, Philippe Moreau, Saad Z Usmani, et al.
Leukemia
|
September 25, 2024
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
María-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
The Lancet. Haematology
|
October 7, 2018
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial
Niels Wcj van de Donk, Bronno van der Holt, Monique C Minnema, et al.
Hemasphere
|
November 15, 2019
Insights on Multiple Myeloma Treatment Strategies
María-Victoria Mateos, Heinz Ludwig, Ali Bazarbachi, et al.
Bone Marrow Transplantation
|
July 26, 2020
Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
Nico Gagelmann, Diderik-Jan Eikema, Liesbeth C de Wreede, et al.
The New England Journal of Medicine
|
February 24, 2021
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C Munshi, Larry D Anderson, Nina Shah, et al.
Haematologica
|
September 2, 2018
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Jo Caers, Laurent Garderet, K Martin Kortüm, et al.
The Lancet. Oncology
|
June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Heinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.
Blood
|
October 8, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
Luca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, et al.
Leukemia Research
|
March 26, 2014
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes
Michel Delforge, Dominik Selleslag, Yves Beguin, et al.
Page
of 19